Destination 1. Staying healthy in a rapidly changing society
HORIZON-HLTH-2023-STAYHLTH-1.01: The Silver Deal - Person-centred health and care throughout the EU
HORIZON-HLTH-2023-STAYHLTH-1.02: Towards a holistic support to children and adolescents’ health and care provisions in an increasingly digital society
HORIZON-HLTH-2023-STAYHLTH- 1.04: Improving population level screening strategies and programmes for non-communicable diseases
HORIZON-HLTH-2024-STAYHLTH- 1.05: Personalised prevention for non- communicable diseases - addressing areas of unmet needs using multiple data sources
Destination 2. Living and working in a health-promoting environment
HORIZON-HLTH-2023-ENVHLTH- 2.01: Planetary health: understanding the links between environmental degradation and health impacts
HORIZON-HLTH-2023-ENVHLTH- 2.02: Evidence-based interventions for promotion of mental and physical health in changing working environments (post-pandemic workplaces)
HORIZON-HLTH-2023-ENVHLTH- 2.03: Research in support of identification and understanding of human health effects of endocrine disrupting chemicals
HORIZON-HLTH-2023-ENVHLTH- 2.04: Global coordination of exposome research
HORIZON-HLTH-2024-ENVHLTH- 2.05: Exposure to hazardous substances (including nanomaterials) or biological agents in occupational environments and adverse health outcomes
HORIZON-HLTH-2024-ENVHLTH- 2.06: The role of environmental pollution in non-communicable diseases: air, noise and light and hazardous waste pollution

Destination 3. Tackling diseases and reducing disease burden
HORIZON-HLTH-2023-DISEASE- 3.01: Palliative and end-of-life care for non-cancer patients
HORIZON-HLTH-2023-DISEASE- 3.03: Interventions in urban environments to reduce NCD risk (GACD)
HORIZON-HLTH-2023-DISEASE- 3.04: Broad spectrum anti-viral therapeutics for infectious diseases with epidemic potential (Pandemic preparedness research)
HORIZON-HLTH-2023-DISEASE- 3.05: Sustaining European Clinical Trial networks for pandemic preparedness and response through well-established coordination mechanisms between EU adaptive platform trials (CSA for pandemic preparedness research)
HORIZON-HLTH-2023-DISEASE- 3.06: Towards a European partnership on brain health
HORIZON-HLTH-2023-DISEASE- 3.07: Relationship between infectious and non- communicable diseases (Comorbidities - relationship between infectious pathogens and non-communicable diseases and its relevance to comorbidities)
HORIZON-HLTH-2024-DISEASE- 3.08: Comparative effectiveness research for healthcare interventions in areas of high public health need
HORIZON-HLTH-2024-DISEASE- 3.09: Contribution to the Global Research Collaboration for Infectious Disease Preparedness (GLOPID-R) coordinated funding initiative (co-programmed preparedness research at international level)
HORIZON-HLTH-2024-DISEASE- 3.10: Integrated management of multimorbidity (GACD)
HORIZON-HLTH-2024-DISEASE- 3.11: Adaptive platform trials for pandemic preparedness (Pandemic preparedness research)
HORIZON-HLTH-2024-DISEASE- 3.12: Maintaining the European partnership for pandemic preparedness (CSA for Pandemic preparedness research)
HORIZON-HLTH-2024-DISEASE- 3.13: Validation of fluid-derived biomarkers for the prediction and prevention of brain disorders
HORIZON-HLTH-2024-DISEASE-3.14: Tackling under-researched high-burden medical conditions
HORIZON-HLTH-2023-DISEASE- P5: European Partnership on Rare Diseases
HORIZON-HLTH-2024-DISEASE- P6: European Partnership: One Health Anti- Microbial Resistance

HERA-specific topics
Destination 4. Ensuring access to innovative, sustainable and high-quality health care
HORIZON-HLTH-2023-CARE- 4.1: Maintaining access to regular care in case of cross-border health emergencies
HORIZON-HLTH-2023-CARE- 4.2: A resilient health and care workforce for the future
HORIZON-HLTH-2023-CARE- 4.3: Environmentally sustainable and decarbonised health and care systems
HORIZON-HLTH-2024-CARE- 4.4: Access to health and care services for vulnerable groups
HORIZON-HLTH-2024-CARE- 4.5: Pre-commercial procurement for environmentally sustainable and low-carbon health and care systems
HORIZON-HLTH-2023-CARE- P4: European Partnership on Personalised Medicine

Destination 5. Unlocking the full potential of new tools, technologies and digital solutions for a healthy society
HORIZON-HLTH-2023-TOOL- 5.01: Clinical trials of Combined ATMPs
HORIZON-HLTH-2023-TOOL- 5.03: Integrated, multi-scale computational models of patient patho-physiology (‘virtual twins’) for personalised disease management
HORIZON-HLTH-2023-TOOL- 5.04: Better integration and use of health-related real-world and research data, including genomics, for improved clinical outcomes, research and innovation
HORIZON-HLTH-2023-TOOL- 5.05: Harnessing the potential of real-time data analysis and secure Point-of-Care computing for the benefit of person-centred health and care delivery
HORIZON-HLTH-2024-TOOL- 5.02: Bio-printing of living cells for regenerative medicine
HORIZON-HLTH-2024-TOOL-5.06: Innovative non-animal human-based tools and strategies for biomedical research
HORIZON-HLTH-2023-IND- 6.01: Supporting the uptake of innovative HTA methodology and advancing HTA expertise across EU
HORIZON-HLTH-2023-IND- 6.02: Expanding the European Electronic Health Record exchange Format to improve interoperability within the European Health Data Space
HORIZON-HLTH-2023-IND- 6.03: Setting up a European wide collaborative mechanism to support the adoption of innovative health solutions across European regions
HORIZON-HLTH-2023-IND- 6.04: Modelling and simulation to address regulatory needs in the development of orphan and paediatric medicines
HORIZON-HLTH-2023-IND- 6.05: Mapping of regulatory requirements for the translation of Advanced Therapy Medicinal Products (ATMP)
HORIZON-HLTH-2023-IND- 6.06: Innovation Partnership 2024 – Development procurement and responsible management of new antimicrobials
HORIZON-HLTH-2024-IND- 6.07: Development and harmonisation of methodologies for assessing digital health technologies in Europe
HORIZON-HLTH-2024-IND- 6.08: Developing an EU methodological framework for clinical/performance evaluation and post-market clinical/performance follow-up of medical devices and in vitro diagnostic medical devices (IVDs)